Last updated: February 19, 2026
What is Empagliflozin?
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Boehringer Ingelheim and Eli Lilly. It is approved for the treatment of type 2 diabetes mellitus (T2DM), reducing blood glucose levels by promoting urinary glucose excretion. Empagliflozin also has indications for heart failure and chronic kidney disease (CKD).
Market Position and Revenue Generation
Empagliflozin is marketed under the brand name Jardiance. Since its approval in 2014, it has grown into a leading SGLT2 inhibitor. As of 2022, empagliflozin has generated approximately $2.5 billion in annual sales globally, accounting for 25% of the overall SGLT2 class revenue. This positions it as a top contender alongside other SGLT2 inhibitors like dapagliflozin (Farxiga) and canagliflozin (Invokana).
Competitive Landscape
| Drug |
Developer |
Indications |
2022 Sales (USD M) |
Market Share (Global, 2022) |
| Jardiance |
Boehringer Ingelheim / Lilly |
T2DM, heart failure, CKD |
2,500 |
40% |
| Farxiga |
AstraZeneca |
T2DM, heart failure, CKD |
1,800 |
29% |
| Invokana |
Janssen (Johnson & Johnson) |
T2DM |
950 |
15% |
Market growth is driven by expanding indications, especially for heart failure and CKD, beyond glucose control.
Regulatory and Clinical Developments
-
FDA Approvals: In 2021, the FDA approved Jardiance for reducing cardiovascular death in adults with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.
-
European Medicines Agency (EMA): Approved for similar indications, including CKD.
-
Ongoing Trials: Confirmatory studies for diabetic nephropathy and heart failure are ongoing, potentially broadening usage and sales.
Revenue Drivers
-
Expanding Indications: Heart failure and CKD indications are responsible for over 30% of Jardiance's sales.
-
Geographical Penetration: The drug has a strong presence in North America, Europe, and Japan; emerging markets are a key growth area.
-
Pricing: Empagliflozin commands premiums in the developed markets, with global average treatment costs around $4 per day.
Cost and R&D Considerations
-
Development Costs: Estimated at $1 billion for global development and commercialization efforts.
-
Pricing Strategy: Premium pricing reflects clinical benefits, with payers increasingly endorsing SGLT2 inhibitors for multiple indications.
-
Patent Life: Patents expire in 2028 in major markets; biosimilar entries could impact pricing and revenue.
Patent Litigation and Biosimilar Entry
- No significant patent litigations threaten empagliflozin until at least 2028.
- Biosimilar competition unlikely, as SGLT2 inhibitors are small molecules, not biologics.
Investment Summary
Strengths
- Strong market position with leading sales in SGLT2 class.
- Rapid growth driven by expanding indications.
- Strategic partnerships with Lilly and Boehringer Ingelheim.
- Significant clinical evidence supporting cardiovascular and renal benefits.
Risks
- Patent expiration in 2028 poses a threat to market exclusivity.
- Price erosion from biosimilars or generics.
- Regulatory shifts restrict accrual of labels or restrict indications.
- Competitive innovation in SGLT2 class or alternative treatments.
Outlook and Valuation
- Anticipated CAGR of 10% in sales through 2025 due to expanded indications.
- Projected peak sales of approximately $4 billion by 2030.
- Market cap implications suggest a forward enterprise value of around $60 billion, assuming sustained sales and margins.
Key Takeaways
- Empagliflozin remains a top-tier SGLT2 inhibitor with diversified indications and stable sales growth.
- The patent cliff in 2028 requires strategic positioning or pipeline development.
- Expanding indications for cardiovascular and renal disease are key growth drivers.
- Pricing and reimbursement strategies are critical in maintaining margins.
- Competitive landscape remains active but manageable due to clinical and label advantages.
FAQs
1. What are the main competitors to empagliflozin?
Dapagliflozin (Farxiga) and canagliflozin (Invokana) lead as primary competitors, offering similar indications with comparable efficacy and safety profiles.
2. What is the patent expiry for empagliflozin?
Patents are valid until 2028 in key markets, after which biosimilar or generics could enter the market and impact sales.
3. How significant are cardiovascular and renal indications for empagliflozin revenue?
They account for approximately 30-40% of current sales, with ongoing studies promising growth in these areas.
4. What regulatory approvals support its expanding use?
The FDA has approved empagliflozin for reducing cardiovascular death in HFrEF patients, with EMA granting approval for CKD and heart failure indications.
5. What areas should investors monitor for risks?
Patent expirations, biosimilar approvals, regulatory restrictions, clinical trial outcomes for new indications, and market penetration in emerging economies.
References
- Bloomberg Intelligence. (2023). Market data for SGLT2 inhibitors.
- EMA. (2021). European approval summaries for Jardiance.
- US FDA. (2021). Prescribing information for Jardiance.
- Pharmaceutical Business Review. (2022). Empagliflozin sales and pipeline updates.
- IQVIA. (2022). Global diabetes drug market analysis.
[1] Ellis, R. P., & Leahy, D. (2022). SGLT2 inhibitors: Market trends and emerging indications. Journal of Pharmacology.
